Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer

BACKGROUND: Platinum doublets are standard first-line treatment for stage IV non-small cell lung cancer (NSCLC) without targetable driver mutations. Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to provide equivalent cytotoxicity. The objective of this study was to evaluate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Ban, Heejung, Kim, Kyu-Sik, Oh, In-Jae, Yoon, Seong-Hoon, Lee, Boram, Yu, Jinyeong, Kim, Sunmin, Lee, Ho-Sung, Shin, Hong-Joon, Park, Cheol-Kyu, Kwon, Yong-Soo, Kim, Yu-Il, Lim, Sung-Chul, Kim, Young-Chul
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704330/
https://ncbi.nlm.nih.gov/pubmed/26767047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12123
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados